Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

Marie Marchand; Nicolas Van Baren; Patrick Weynants; Vincent Brichard; Brigitte Dréno; Marie Hélène Tessier; Elaine Rankin; Giorgio Parmiani; Flavio Arienti; Yves Humblet; André Bourlond; Romain Vanwijck; Danielle Liénard; Marc Beauduin; Pierre Yves Dietrich; Vincenzo Russo; Joseph Kerger; Giuseppe Masucci; Elke Jäger; Jacques De Greve; Jens Atzpodien; Francis Brasseur; Pierre G. Coulie; Pierre Van Der Bruggen; Thierry Boon

doi:10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

Marie Marchand, Nicolas Van Baren, Patrick Weynants, Vincent Brichard, Brigitte Dréno, Marie Hélène Tessier, Elaine Rankin, Giorgio Parmiani, Flavio Arienti, Yves Humblet, André Bourlond, Romain Vanwijck, Danielle Liénard, Marc Beauduin, Pierre Yves Dietrich, Vincenzo Russo, Joseph Kerger, Giuseppe Masucci, Elke Jäger, Jacques De GreveJens Atzpodien, Francis Brasseur, Pierre G. Coulie, Pierre Van Der Bruggen, Thierry Boon

Research output: Contribution to journal › Article

Abstract

Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.

Original language	English
Pages (from-to)	219-230
Number of pages	12
Journal	International Journal of Cancer
Volume	80
Issue number	2
DOIs	https://doi.org/10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S
Publication status	Published - Jan 18 1999

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

Fingerprint Dive into the research topics of 'Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1'. Together they form a unique fingerprint.

Cite this

Marchand, M., Van Baren, N., Weynants, P., Brichard, V., Dréno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Liénard, D., Beauduin, M., Dietrich, P. Y., Russo, V., Kerger, J., Masucci, G., Jäger, E., ... Boon, T. (1999). Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. International Journal of Cancer, 80(2), 219-230. https://doi.org/10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. / Marchand, Marie; Van Baren, Nicolas; Weynants, Patrick; Brichard, Vincent; Dréno, Brigitte; Tessier, Marie Hélène; Rankin, Elaine; Parmiani, Giorgio; Arienti, Flavio; Humblet, Yves; Bourlond, André; Vanwijck, Romain; Liénard, Danielle; Beauduin, Marc; Dietrich, Pierre Yves; Russo, Vincenzo; Kerger, Joseph; Masucci, Giuseppe; Jäger, Elke; De Greve, Jacques; Atzpodien, Jens; Brasseur, Francis; Coulie, Pierre G.; Van Der Bruggen, Pierre; Boon, Thierry.

In: International Journal of Cancer, Vol. 80, No. 2, 18.01.1999, p. 219-230.

Research output: Contribution to journal › Article

Marchand, M, Van Baren, N, Weynants, P, Brichard, V, Dréno, B, Tessier, MH, Rankin, E, Parmiani, G, Arienti, F, Humblet, Y, Bourlond, A, Vanwijck, R, Liénard, D, Beauduin, M, Dietrich, PY, Russo, V, Kerger, J, Masucci, G, Jäger, E, De Greve, J, Atzpodien, J, Brasseur, F, Coulie, PG, Van Der Bruggen, P & Boon, T 1999, 'Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1', International Journal of Cancer, vol. 80, no. 2, pp. 219-230. https://doi.org/10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

Marchand, Marie ; Van Baren, Nicolas ; Weynants, Patrick ; Brichard, Vincent ; Dréno, Brigitte ; Tessier, Marie Hélène ; Rankin, Elaine ; Parmiani, Giorgio ; Arienti, Flavio ; Humblet, Yves ; Bourlond, André ; Vanwijck, Romain ; Liénard, Danielle ; Beauduin, Marc ; Dietrich, Pierre Yves ; Russo, Vincenzo ; Kerger, Joseph ; Masucci, Giuseppe ; Jäger, Elke ; De Greve, Jacques ; Atzpodien, Jens ; Brasseur, Francis ; Coulie, Pierre G. ; Van Der Bruggen, Pierre ; Boon, Thierry. / Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. In: International Journal of Cancer. 1999 ; Vol. 80, No. 2. pp. 219-230.

@article{1eef1c23246641d3b566d96152a1b18f,

title = "Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1",

abstract = "Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.",

author = "Marie Marchand and {Van Baren}, Nicolas and Patrick Weynants and Vincent Brichard and Brigitte Dr{\'e}no and Tessier, {Marie H{\'e}l{\`e}ne} and Elaine Rankin and Giorgio Parmiani and Flavio Arienti and Yves Humblet and Andr{\'e} Bourlond and Romain Vanwijck and Danielle Li{\'e}nard and Marc Beauduin and Dietrich, {Pierre Yves} and Vincenzo Russo and Joseph Kerger and Giuseppe Masucci and Elke J{\"a}ger and {De Greve}, Jacques and Jens Atzpodien and Francis Brasseur and Coulie, {Pierre G.} and {Van Der Bruggen}, Pierre and Thierry Boon",

year = "1999",

month = jan,

day = "18",

doi = "10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S",

language = "English",

volume = "80",

pages = "219--230",

journal = "International Journal of Cancer",

issn = "0020-7136",

publisher = "Wiley-Liss Inc.",

number = "2",

}

TY - JOUR

T1 - Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

AU - Marchand, Marie

AU - Van Baren, Nicolas

AU - Weynants, Patrick

AU - Brichard, Vincent

AU - Dréno, Brigitte

AU - Tessier, Marie Hélène

AU - Rankin, Elaine

AU - Parmiani, Giorgio

AU - Arienti, Flavio

AU - Humblet, Yves

AU - Bourlond, André

AU - Vanwijck, Romain

AU - Liénard, Danielle

AU - Beauduin, Marc

AU - Dietrich, Pierre Yves

AU - Russo, Vincenzo

AU - Kerger, Joseph

AU - Masucci, Giuseppe

AU - Jäger, Elke

AU - De Greve, Jacques

AU - Atzpodien, Jens

AU - Brasseur, Francis

AU - Coulie, Pierre G.

AU - Van Der Bruggen, Pierre

AU - Boon, Thierry

PY - 1999/1/18

Y1 - 1999/1/18

N2 - Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.

AB - Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced.

UR - http://www.scopus.com/inward/record.url?scp=0033579934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033579934&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

DO - 10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S

M3 - Article

C2 - 9935203

AN - SCOPUS:0033579934

VL - 80

SP - 219

EP - 230

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -